R&D News | pharmaphorum

News

Dr Yu Xia, founder, chairwoman, president and chief executive of Akeso

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Akeso has bagged an FDA approval for its PD-1 inhibitor penpulimab and reported new data on highly-touted PD-1/VEGF bispecific ivonescimab.

News

Granite Bio makes $100m debut, and other bio financings

Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.

News

Hands uniting in the centre of a circle of children

Irish study promises to revolutionise childhood cancer care

A five-year genomics study that aims to transform the care of children with cancer and improve treatment success has launched in Ireland.

News

Can Bioxodes end the dearth of haemorrhagic stroke drugs?

There is currently no approved treatment for intracerebral haemorrhagic stroke, but Belgian start-up Bioxodes hopes to change that.

News

AstraZeneca joins Tempus, Pathos in cancer AI project

AstraZeneca has started work with Tempus and Pathos AI on a $200m project to build a comprehensive multimodal foundation model for oncology.

News

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Cancer drug developer Veraxa Biotech has reached a deal to merge with a SPAC in a deal that will give it a Nasdaq listing and a $1.6bn-plus valuation.

Akeso PD-1 inhibitor cleared as Keytruda challenger advances

Granite Bio makes $100m debut, and other bio financings

Irish study promises to revolutionise childhood cancer care

Can Bioxodes end the dearth of haemorrhagic stroke drugs?

AstraZeneca joins Tempus, Pathos in cancer AI project

Swiss biotech Veraxa vaults to Nasdaq listing with SPAC deal

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks